#United Kingdom #Oxford #Clinical Trials #Albus Health #Nocturnal Monitoring

Albus Health's Strategic Leadership Expansion

In a significant move to bolster its global presence, Albus Health, a frontrunner in multimodal nocturnal health monitoring, has expanded its senior leadership team with two essential appointments. As the company ramps up its efforts to deliver contactless, clinical-grade monitoring solutions suitable for multinational clinical trials, these appointments are pivotal for supporting their expansive vision.

New Faces in Leadership

Jonathan Day has joined Albus Health as the Head of Quality Assurance and Regulatory Affairs, while Dr. Samantha Macro has taken on the role of fractional Chief Financial Officer. Their addition is seen as a vital step toward enhancing the company's capability to provide regulator-ready, meaningful nocturnal health data on a grand scale. This data will streamline the process for clinical trials ranging from initial research phases to commercial application efforts.

The centerpiece of Albus Health's offerings is its flagship product, the Albus Home system, which employs cutting-edge sensors and artificial intelligence algorithms to continuously monitor vital nocturnal parameters. This includes the recording of cough, vital signs, sleep quality, and various environmental factors. Currently operational in over 50 countries, Albus Home significantly supports pharmaceutical firms, research institutions, and patient advocacy groups as they navigate the complexities of clinical research and chronic disease management.

Leadership with Experience

Mikesh Udani, Co-founder and CEO of Albus Health, emphasized the importance of these appointments in elevating the company's operational capabilities. "With market adoption growing rapidly, we are fortifying the structures that will help maximize the value our users derive from Albus," he stated. He underscored that both Samantha and Jonathan bring a wealth of knowledge and experience from their previous roles within the pharmaceutical and healthcare sectors, particularly during growth phases of their respective organizations.

Jonathan Day's career encompasses over 25 years in the medical device and Software as a Medical Device (SaMD) fields, covering essential territories such as the United States, the United Kingdom, and Switzerland. His extensive background includes formulating regulatory strategies, generating quality compliance programs, overseeing process optimizations, and guiding new product introductions through their critical phases.

Samantha Macro, with more than 20 years of finance leadership in biotech and renowned pharmaceutical companies, has held both fractional and full-time CFO positions at major organizations including AstraZeneca and Cambridge Antibody Technology. Her expertise ranges from securing significant seed funding—totaling up to $45 million—to spearheading strategic mergers and acquisitions, all notably during preparations for an IPO on NASDAQ.

A Robust Management Team

Joining this dynamic leadership team is not just an enhancement but a consolidation of Albus Health's established Board of Directors, which includes various distinguished clinicians and researchers in respiratory health and sleep studies, as well as medtech industry veterans. Noteworthy members include Co-founders Mikesh Udani and Dr. William Do, alongside Non-Executive Director Colin Reisner, former CEO of Pearl Therapeutics, and a medical professional with vast industry leadership experience across prominent pharmaceutical companies such as AstraZeneca, GSK, Novartis, and Boehringer Ingelheim.

About Albus Health

Albus Health champions the development of innovative contactless nocturnal monitoring systems. These systems serve not only to facilitate clinical trials and real-world evidence programs but also play an invaluable role in the ongoing management of chronic diseases. More information about their groundbreaking work can be found on their official website: www.albushealth.com. With this strategic expansion of its leadership, Albus Health is poised to continue its ascent in the rapidly evolving landscape of medical technology and health monitoring solutions.